Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically proven mycosis fungoides or Sezary syndrome
• •* Any stage
• •Measurable disease with 1 or more indicator lesions
• •* Evaluable disease for erythrodermic patients only
• •At least 2 weeks since prior therapy, if documented progressive disease (PD)
• •At least 4 weeks since prior therapy, if best response achieved without clear evidence of PD
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •WBC at least 3,000/mm\^3
• •Absolute granulocyte count at least 1,000/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 2.2 mg/dL
• •Renal:
• •Creatinine no greater than 2.0 mg/dL
• •Cardiovascular:
• •No New York Heart Association class III or IV heart disease
• •No cardiac pacemaker
• •No clinically significant peripheral venous insufficiency
• •Other:
• •No other malignancy within the past 5 years except:
• •* Treated squamous cell or basal cell skin cancer
• •* Treated carcinoma in situ of the cervix
• •* Surgically treated other cancer
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active infection
• •HIV negative
• •No poorly controlled diabetes mellitus
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •Endocrine therapy:
• •No concurrent steroids
• •Radiotherapy:
• •See Disease Characteristics
• •No concurrent radiotherapy
• •Surgery:
• •Not specified
• •Other:
• •No other concurrent proven or investigational antineoplastic therapy